A new target in multiple myeloma? TAK1 blocker boosts chemo's cancer-killing power in preclinical study
Fierce Biotech,
Several new therapies have been approved in recent years to treat multiple myeloma, greatly extending the life expectancy for…
Several new therapies have been approved in recent years to treat multiple myeloma, greatly extending the life expectancy for…
Oncotarget published “TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan” which…
Impact Journals LLC Oncotarget published “ alone and in combination with melphalan” which reported that TAK1 is an attractive…